SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study)
SUO 2020: Debate: Relugolix for Advanced Prostate Cancer is the New Standard (The HERO Study) (UroToday.com) During the second prostate cancer session at the 2020 Annual Meeting of the Society of Urologic Oncology (SUO), Drs. Neal Shore and Ashley Evan Ross debated the use of relugolix as a new standard of care for androgen deprivation therapy (ADT) for the treatment of prostate cancer. This debate follows the publication of the HERO trial, 1 A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO), which was published in the New England Journal ...
Source: urotoday.com